HLA B27 (Ankylosing Spondylitis)
|Disease:||• Pharmacogenetics/Ocular Immunogenetics • Rheumatoid Arthritis|
|Methodology:||Sequence Specific Primers|
|Reference Range:||No established reference ranges. Reported positive or negative|
|Note:||New York State Clients: EDTA specimens should be analyzed within 48 hours of collection.|
|CPT Code:||83891, 83894, 83912, 83898 (x19)|
|Schedule / Turnaround Time:||Assay performed daily. Report availability is within 48 hours from the time of specimen receipt.|
Specimen must be kept in ambient temperature and should not be refrigerated or frozen. Collect 5 ml of blood in a lavender top Hemogard (EDTA) tube.
Sample is stable at ambient temperature and should be analyzed within 76 hours.
The HLA-B27 genetic marker, in particular the *27:02, *27:04, and *27:05 subtypes, are strongly associated with conditions collectively referred to as seronegative arthropathies. At the forefront of these syndromes is the disease ankylosing spondylitis (AK). AK, a rheumatic condition primarily affecting the spine and axial skeleton, may also involve multiple organ systems. Generally, 95% of patients with AK express a B27 susceptibility marker as compared to 3-5% of the non-afflicted population.Other diseases with similar features are also strongly associated with HLA-B27. Among patients experiencing reactive arthritis, an autoimmune response to gastrointestinal infections, 60-70% exhibit the HLA-B27 marker. Spinal and peripheral joint inflammation occurring in conjunction with psoriasis and inflammatory bowel disease, and anterior uveitis, show similar associations with HLA-B27.